Evaluation of the effectiveness and safety of interferon alpha-2b ointment and gel for prevention of acute respiratory infections in organized groups

Author:

Kozlov K. V.1,Zhdanov K. V.1,Maltsev O. V.1,Kasyanenko K.1,Sigidaev A. S.2,Lyashenko Yu. I.1,Kozlov S. S.1,Sidorchuk S. N.1,Saulevich A. V.1,Sukachev V. S.1

Affiliation:

1. Military Medical Academy named after S.M. Kirov

2. Tyumen State Medical University

Abstract

Relevance: the annual incidence of acute respiratory infections (ARI) is in the lead in the structure of infectious pathology in the Russian Federation. One of the main issues is the development of optimal strategies for prevention of these diseases in high-risk groups.Aim: to evaluate the preventive and clinical efficacy as well as safety of various dosage forms of interferon alpha-2b in relation to ARI in young adults from organized groups.Materials and methods: our study included 300 volunteers aged 18 to 20 years, 100 of them were prescribed interferon alpha-2b in the form of a gel in addition to non-specific methods for the prevention of ARVI, 100 participants received interferon alpha-2b in the form of an ointment, 100 participants did not receive antiviral drugs.Results: the use of interferon alpha-2b ointment for prevention of ARI in organized groups significantly reduced the number of people who had ARVI and cases of ARI during the observation period. Among those who used interferon alpha2b no pneumonias occurred, the duration of hospitalization was statistically significantly reduced compared to the group of volunteers who used only non-specific prophylaxis methods. Participants who received interferon alpha-2b ointment had ARVI mainly in a mild form. No adverse events that could be associated with the use of the study drug were recorded during the observation period.Conclusion: the use of interferon alpha-2b in the form of ointment showed preventive and clinical efficacy against ARI in young adults from organized groups.

Publisher

SPRIDA

Reference20 articles.

1. Hadjadj, J. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients / J. Hadjadj, N. Yatim, L. Barnabei, A. Corneau, J, Boussier, N. Smith, H. Péré, B. Charbit, V. Bondet, C. Chenevier-Gobeaux, P. Breillat, N. Carlier, R. Gauzit, C. Morbieu, F. Pène, N. Marin, N. Roche, T.A. Szwebel, S.H. Merkling, J.M. Treluyer, D. Veyer, L. Mouthon, C. Blanc, P.L. Tharaux, F. Rozenberg, A. Fischer, D. Duffy, F. Rieux-Laucat, S. Kernéis, B. Terrier // Science. – 2020. – Vol. 7. – № 369(6504). – P. 718-724.

2. Mesic, A. Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies / A. Mesic, E.K. Jackson, M. Lalika, D.M. Koelle, R.C. Patel // PLOS Glob Public Health. – 2022. – Vol. 6. – № 2. – Article.e0000231.

3. Zhongji, M. Experimental Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in an Epidemic Area / M. Zhonhji, W. Tongyu, C. Li, C. Xinhe, L. Longti, Q. Xueqin, L. Hai, L. Jie // medRxiv. –2020.

4. Miyachi, K. Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis / K. Miyachi, T. Iwamoto, S. Kojima, T. Ida, J. Suzuki, T. Yamamoto, N. Mimura, T. Sugiyama, S. Tanaka, S. Furuta, K. Ikeda, K. Suzuki, T.B. Niewold, H. Nakajima // Arthritis Res Ther. – 2023. – Vol. 17. – № 25(1). – P. 26.

5. Schreiber, G. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 // Front Immunol. – 2020. – Vol. 30. – № 11. – P. 595739.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3